[Topography of bacteriophage T7 RNA polymerase using monoclonal antibodies]
Abstract:
Four clones producing monoclonal antibodies inhibiting enzymatic activity were used to localize the functionally important antigenic determinants of T7 RNA polymerase. All antibodies were shown to bind to C-terminal fragment of the protein (residues 589-883). The competition studies showed the specificity of the three antibodies toward one epitope and the fourth antibody to another one. By means of limited cleavage of the RNA polymerase with cyanogen bromide with subsequent electrophoretic separation and immunoblotting the peptides containing antigenic determinants were localized. These are Met861-Ala883 for antibody 4H8 and Met750-Met832 for antibodies 9B2, 3H11 and 2A2.
Insights
Monoclonal antibodies were used to map key regions of T7 RNA polymerase. Researchers identified two distinct epitopes on the C-terminal fragment, crucial for enzyme function.
Area of Science:
- Molecular Biology
- Immunochemistry
Context:
- T7 RNA polymerase is a vital enzyme in viral replication.
- Understanding its structure-function relationship is key to developing antiviral strategies.
- Monoclonal antibodies offer precise tools for probing protein epitopes.
Purpose:
- To identify and localize the specific antigenic determinants on T7 RNA polymerase that are critical for its enzymatic activity.
- To characterize the binding sites of monoclonal antibodies that inhibit T7 RNA polymerase function.
Summary:
- Four monoclonal antibodies inhibiting T7 RNA polymerase activity were generated and characterized.
- All antibodies recognized epitopes within the C-terminal fragment (residues 589-883).
- Competition assays revealed two distinct epitopes: one recognized by antibody 4H8 (Met861-Ala883) and another by antibodies 9B2, 3H11, and 2A2 (Met750-Met832).
Impact:
- Provides precise mapping of functionally significant epitopes on T7 RNA polymerase.
- Facilitates structure-based drug design targeting T7 RNA polymerase.
- Enhances understanding of enzyme-antibody interactions for potential therapeutic interventions.
